The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I):

##STR00001##

wherein X, Y, Z, R.sub.1, R.sub.2, R.sub.4 and R.sub.7 are defined herein.

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I):

##STR00001##

wherein X, Y, Z, R.sub.1, R.sub.2, R.sub.4 and R.sub.7 are defined herein.

The present disclosure relates to novel synthetic method of making 1, 4-diazo N-heterocycles via intermolecular amphoteric diamination of allenes, and to the compounds made by the novel synthetic method.

The present disclosure relates to novel synthetic method of making 1, 4-diazo N-heterocycles via intermolecular amphoteric diamination of allenes, and to the compounds made by the novel synthetic method.

The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.

The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.

The present invention discloses a cast-in-place protective sheet, comprising the main ingredient taking up 45%-95% of the total by weight, which is composed of 125-140 parts of isocyanate, 10-220 parts of polyamine compound, 220-660 parts of diamine compound, 210-260 parts of polyether diol and 115-190 parts of polyether polyol, as well as the excipient taking up 5%-55% of the total by weight which is composed of 20-140 parts of environmental diluent, 1-35 parts of organometallic catalyst, 30-400 parts of filler and 4-75 parts of deforming agent. The present invention is an environmentally-friendly seamless waterproof material which has the advantages of strong adaptability to the environment, fast curing and good flexibility.

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I):

##STR00001##

wherein X, Y, Z, R.sub.1, R.sub.2, R.sub.4 and R.sub.7 are defined herein.

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I):

##STR00001##

wherein X, Y, Z, R.sub.1, R.sub.2, R.sub.4 and R.sub.7 are defined herein.

Bradykinin B1 receptor (B1R) targeting peptides and compounds are radiolabelled with radioisotopes that are suitable for imaging and/or radiotherapy. The radiolabelled peptides and compounds have utility in imaging tissues expressing or overexpressing B1R and/or treating diseases or conditions in which B1R is expressed or overexpressed, including cancer.